Clinical trials: Countermeasure Evaluation
Hematopoietic Syndrome Due to Acute Radiation Syndrome
Safety and Tolerability of HemaMax™ (rHuIL-12) as Radiation Countermeasure
This trial is designed to evaluate the safety, pharmacokinetics, and pharmacodynamics of HemaMax in healthy male and female volunteers.
- Trial name
- NCT01742221
- Testing
- HemaMax
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Neumedicines Inc.